Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc., Corona, CA, signed an agreement to acquire CoCensys Pharmaceutical's neurology and psychiatry sales and marketing divisions.
Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc., Corona, CA, signed an agreement to acquire CoCensys Pharmaceutical's neurology and psychiatry sales and marketing divisions.
The transaction, valued at approximately $9 million, also entitles Watson to the Irvine, CA-based company's newly acquired central nervous system product and co-promotion agreements for Somerset Pharmaceuticals' Parkinson's disease product Elderpryl and Parke-Davis' children's epilepsy product Zarontin.
"The CoCensys sales and marketing division was particularly attractive because the sales force is well-established and expert in the areas of neurology and psychiatry," said Allan Chao, Watson's chairman and chief executive officer. "They will complement our existing primary and recently established female health care sales forces."
CoCensys says it will benefit from the sale because it will be able to streamline and concentrate energies and resources on discovering and developing therapies for brain and central nervous system disorders. Its sales organization, meanwhile, will "benefit by being part of an operating environment that possesses a large portfolio of products and the significant resources to maximize its marketing capabilities," according to F. Richard Nichol, CoCensys' president and chief executive officer.
The companies plan to collaborate in the future as CoCensys brings new products to market. PR
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.